New Myeloma Combo (carfilzomib/dara/dex) Submitted for FDA Approval
Posted: Feb 13, 2020
New Myeloma Combo (carfilzomib/dara/dex) Submitted for FDA Approval image

A new combination of multiple myeloma therapies has been submitted for FDA approval this week. Janssen submitted the request to the FDA for the use of daratumumab (Darzalex), carfilzomib (Kyprolis) and dexamethasone for relapsed or refractory multiple myeloma treatment.

The request was made based on the results of the CANDOR study data, a Phase III study that compared the triplet (carfilzomib/dara/dex) with a doublet (carfilzomib/dex) for patients who had relapsed after 1-3 prior lines of treatment.

The idea of using myeloma therapies in combination without an immunomodulator (lenalidomide or pomalidomide) is a new one. While immunomodulators are considered a “standard” in myeloma combinations, some patients relapse after these drugs and patients are left without effective options. This new combination would provide a powerful alternative for patients in that situation.

In the CANDOR study, 466 relapsed myeloma patients were divided into the KDd arm or the Kd arm.

The study endpoint was progression free survival, or how long patients lived without relapsing. Study results included:

Progression free survival at 17 months:

  • 37% lowered risk of disease progression in the KdD arm
  • Median progression free survival wasn’t reached by the end of 17 months for the KdD arm
  • Median progression free survival was 15.8 months for the Kd arm

Overall response rates:

  • 84.3% for KDd patients
  • 74.7% for Kd patients

Patients had a better depth of response as well. Minimal residual disease (MRD) negativity at one year was 10x better with the triplet combination.

  • 12.5% for KDd patients
  • 1.3% for Kd patients

The addition of daratumumab made a big difference. We hope to see rapid FDA approval as all of these drugs have already been approved in other myeloma combinations and we look forward to patients having one more option.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811